title: Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1.
abstract: Ligation of CD40 on the surface of B cells induces multiple phenotypic effects, many of which are mimicked by the EBV latent membrane protein 1 (LMP1) through its interaction with downstream components of the CD40 signaling pathway. Because the effects of LMP1 have been most closely studied in human Burkitt Lymphoma (BL) cell lines retaining a tumor biopsy-like phenotype in vitro, we have examined the response of a panel of such lines to CD40 ligation. Two distinct patterns of response were observed that were unrelated to the surface level of CD40 or to the EBV genome status of the lines. Following exposure to either CD40-specific mAbs or the soluble trimeric ligand (sCD40L), high responder (HR) lines showed rapid aggregation, activation of NF-kappa B, up-regulation of cell surface markers ICAM-1/CD54 and Fas/CD95, and growth inhibition. Aggregation was seen at lower doses than those required to elicit the other effects. By contrast, low responder (LR) lines showed no detectable response to CD40 mAbs, while their responses to sCD40L were limited to activation of NF-kappa B and up-regulation of CD95 only. However, in transfection experiments, LMP1 uniformly induced the full spectrum of phenotypic effects in both HR and LR lines. We conclude that some BL cell lines show a highly restricted response to CD40 ligation but remain fully susceptible to LMP1.
authors: Cancer Research Campaign, University of Birmingham, United Kingdom.
authors: N V
authors: NV
authors: Henriquez
authors: E
authors: E
authors: Floettmann
authors: M
authors: M
authors: Salmon
authors: M
authors: M
authors: Rowe
authors: A B
authors: AB
authors: Rickinson
mesh_terms: D002051:Burkitt Lymphoma / Q000276:immunology* / Q000378:metabolism / Q000821:virology; D019013:CD40 Antigens / Q000276:immunology / Q000378:metabolism* / Q000494:pharmacology; D023201:CD40 Ligand; D002449:Cell Aggregation / Q000235:genetics / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis; D008024:Ligands; D008562:Membrane Glycoproteins / Q000276:immunology / Q000378:metabolism* / Q000494:pharmacology; D016328:NF-kappa B / Q000378:metabolism; D014162:Transfection; D014407:Tumor Cells, Cultured; D015854:Up-Regulation / Q000276:immunology; D014763:Viral Matrix Proteins / Q000235:genetics / Q000502:physiology*; D019014:fas Receptor / Q000096:biosynthesis
chemical_list: D019013:CD40 Antigens; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D008024:Ligands; D008562:Membrane Glycoproteins; D016328:NF-kappa B; D014763:Viral Matrix Proteins; D019014:fas Receptor; D018799:Intercellular Adhesion Molecule-1; D023201:CD40 Ligand